Pre-made Briakinumab biosimilar ( Whole mAb, anti-IL12B therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-081
Anti-IL12B therapeutic antibody (Pre-made Briakinumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Briakinumab (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL12B therapeutic antibody (Pre-made Briakinumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Preregistration (w)|
|100% SI Structure||5n2k:LK:BA:PO:DC:NM:FE|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Cambridge Antibody Technology;Abbott GmbH & Co. KG|
|Conditions Discontinued||Plaque psoriasis;Crohn's disease;Multiple sclerosis;Rheumatoid arthritis|